Samsung Biologics signs strategic agreement with Kurma Partners

Samsung Biologics has signed a strategic agreement with Kurma Partners for the development and manufacturing of biologics for Kurma's client companies. The deal will leverage Samsung Biologics' facilities and expertise.

Samsung Biologics CEO John Rim speaks during a press event held at Samsung Biologics’ headquarters in Incheon. [SAMSUNG BIOLOGICS]

Samsung Biologics signed a strategic agreement with Paris-based Kurma Partners for the development and manufacturing of biologics for Kurma's client companies.

Under the multiyear agreement, Samsung Biologics will provide customizable chemistry, manufacturing, and control (CMC) development services for Kurma Partners’ portfolio companies from the very early stage of the development to further clinical development.

The portfolio companies will be able to leverage Samsung Biologics’ facilities, proprietary technology platforms, and CMC-related expertise, the Korean company said.

Founded in 2009, Kurma Partners is an investment firm specializing in the health care market.

The latest agreement reflects Samsung Biologics’ continued commitment to supporting emerging biotech companies on their drug development and manufacturing journey as well as further increasing its business presence in major sectors with a focus on the U.S. and European markets, it said.

“As we look to further expand our business opportunities globally, we are pleased to collaborate with Kurma Partners to support the growth of pioneering biotech companies,” said Samsung Biologics CEO John Rim. “With our in-depth knowledge of effective scale-up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance, and ultimately maximize manufacturing efficiency for our clients.”

BY SARAH CHEA [chea.sarah@joongang.co.kr]